Kura Oncology (KURA) said Tuesday it submitted a new drug application to the US Food and Drug Administration for ziftomenib to potentially treat adults with relapsed or refractory acute myeloid leukemia with an NPM1 mutation.
The biotechnology company said the FDA has 60 days to determine if the NDA is complete and accepted for review. Kura has requested priority review, which, if granted, would set a six-month review timeline after acceptance, the company said.
Kura said ziftomenib has received breakthrough therapy, fast track and orphan drug designations.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。